Vir Bio's Cancer Treatment Progress Driving Shares Hight | Bloomberg Businessweek

Описание: Vir Biotechnology Vir is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. The company on Monday announced new data from the ongoing Phase 1 clinical trial of VIR-5500, a prostate-specific membrane antigen (PSMA)-targeting, PRO-XTEN dual-masked T-cell engager (TCE) being evaluated in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) who have progressed after multiple lines of therapy. These data suggest that VIR-5500 monotherapy is well tolerated and exhibits promising anti-tumor activity.

Marianne De Backer, Ph.D., the CEO at Vir Bio, discusses the progress being made with the firm's leading treatments, the runup in its share price thus far in 2026, and why partnerships are key to advancing Vir's impact. Dr. De Backer speaks with Carol Massar and Tim Stenovec on Bloomberg Businessweek Daily.
See omnystudio.com/listener (https://omnystudio.com/listener) for privacy information.


Carol Massar and Tim Stenovec bring together the latest news from the world of business and finance and the interesting stories of global technology, politics, economics and more by harnessing the power of Bloomberg Businessweek reporters and editors.

Subscribe to Bloomberg Podcasts: https://bit.ly/BloombergPodcasts
Listen to more of Bloomberg Businessweek:    • Bloomberg Businessweek  

#Bloomberg #Podcast #News #Businessweek

Visit us: https://www.bloomberg.com/podcasts

Follow Bloomberg Podcasts on Twitter:   / podcasts  

Visit our other YouTube channels:
Bloomberg Television:    / @markets  
Bloomberg Originals:    / bloomberg  
Quicktake:    / @bloombergquicktake  

For coverage on news, markets and more: http://www.bloomberg.com/video